

Synopsis

"Biopreneurs: The Molecular Millionaires" has tried to cover the ordinary and extraordinary resources that readers can utilize to understand the biotech industry. While writing the book, writers even have thought for those without biotech backgrounds. Thus, the book does not emphasize dry facts from the life science subject, or financial figures from the stock market. It is, rather, a lucid situational analysis of the biotech industry.

"Biopreneurs: The Molecular Millionaires" offers a historical perspective of the biotech industry, advancement of biotech industry in relation to the recent growth and excitement of genomics and tissue regeneration sciences. It has also covered the highlights for investing in specific areas of biotechnology, for instance, diabetes, cancer, strokes, agerelated diseases, etc. It also strives to identify, analyze and educate prospective investors about how and why to invest in startup ventures, early-stage companies and mid-sized corporations. In addition, it will also provide tools, knowledge, and expertise to identify appropriate time to realize profits in a particular field, which will be done using a three-dimensional model for the biotech industry.

It presents from historical to clinical, from marketing to investment, from invention to distribution and last but not the least from university to the field of concrete business. It has been designed for the betterment of every stratum of people associated with or willing to join biotechnology. In a nutshell, it has earnestly desired to incorporate as much information as possible to make the book a best friend, philosopher and guide for the people interested in biotechnology.

"Biopreneurs: The Molecular Millionaires" depicts with equal ease the various stages of drug development as well as the stages of designing market strategy. And it's possible only because of the expertise of much experienced hands of well-known biopreneurs Dr. Ryan Baidya and Miyuki Shiratani. The book is full, balanced, deserving a reading, yet has scope to be developed, which is literally impossible without the readers' feedback.

Table of Contents

<u>Topic</u>	Pages
1) Prelude	07-08
2) Chapter I	09-18
Biopreneurship: Entrepreneurship in Biotechnology	10
Crossing the Boundaries	10
Uncertainty and Biopreneurship	12
Uncertainty opens the Door for Opportunities	13
Molecular Millionaires	14
Steps towards Biopreneurship	15
Most of us dream to be a Biopreneur	16
A Calling	17
3) Chapter II	19-27
Who is Biopreneur?	20
Valuable Opinions	21
A Leadership: well-expected	22
Simple Philosophy	23
Inside the Minds of Biopreneurs	24
Path to Success	24
Success Redefined	25
Sum up	27
4) Chapter III	28-38
What is Biotechnology?	29
History and Development of the Industry	29
Characteristics of the Industry	30
Understanding the Drug Discovery Process	30
Research and Development	32
Animal Model Selection for Efficacy Studies	33
Casualty of the R&D	33
Future Drug Development Process	34
Business decision-making Infrastructure	35
Conclusion	38
5) Chapter IV	39-54
Preclinical Development	40
Drug discovery: A Brief Story	40
From Developability Decision to Clinical Proof of Concept	41
Establishing Developability	41
Pre-clinical Development (Table)	42
Animal Testing	45
History in Brief	45
Types of animals used	45
Safety Assessment in using Animals/in Preclinical Studies	47
Dose Selection	48
Pharmacodynamics/Biological Activities	49

Clinical Research	Pharmacokinetics and Toxicokinetics	50
Preclinical Development 51	Immunogenicity	50
Clinical Research 56 What is a Clinical Trial – the process 58 Clinical Proof of Concept 58 Few Important Notes 59 Phases/Stages of Clinical Trial 61 Phase II 62 Phase III 64 Phase III 65 Phase IV 62 Regulation and Safety of Patient 64 Pre-clinical Safety Assessment 64 Pre-Approval Safety Assessment 64 Pre-Approval Safety Assessment in Humans 64 Pre-Approval Safety Assessment in Humans 64 Pre-Approval Safety Assessment in Humans 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Business Plan Business Planning 71 Executive Summary 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Technology Description 72 Technology Description 73 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 Strategy 74 R&D 75 Pinancing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Bioventure 80 Financing Strategy – From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	- · · · · · · · · · · · · · · · · · · ·	51
What is a Clinical Trial? 56 Clinical Trial – the process 58 Clinical Proof of Concept 58 Few Important Notes 59 Phases/Stages of Clinical Trial 61 Phase I 61 Phase II 62 Phase III 62 Phase IV 62 Regulation and Safety of Patient 64 Pre-clinical Safety Assessment 64 Pre-Approval Safety Assessment in Humans 64 Safety Assessment during FDA Regulatory Review 65 Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Technology Description and Competitiveness	6) Chapter V	55-69
Clinical Trial - the process 58	Clinical Research	56
Clinical Proof of Concept 58	What is a Clinical Trial?	56
Few Important Notes 59 Phases/Stages of Clinical Trial 61 Phase I 62 Phase II 62 Phase IV 62 Regulation and Safety of Patient 64 Pre-clinical Safety Assessment 64 Pre-clinical Safety Assessment in Humans 64 Safety Assessment during FDA Regulatory Review 65 Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 For a stage of the stage of	Clinical Trial – the process	58
Phases/Stages of Clinical Trial 61 Phase II 62 Phase III 62 Phase IV 62 Regulation and Safety of Patient 64 Pre-clinical Safety Assessment 64 Pre-Approval Safety Assessment in Humans 64 Safety Assessment during FDA Regulatory Review 65 Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76	Clinical Proof of Concept	58
Phase I	Few Important Notes	59
Phase III 62 Phase III 62 Phase IV 62 Regulation and Safety of Patient 64 Pre-clinical Safety Assessment 64 Pre-Approval Safety Assessment in Humans 64 Safety Assessment during FDA Regulatory Review 65 Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to	Phases/Stages of Clinical Trial	61
Phase III	Phase I	61
Phase IV	Phase II	62
Regulation and Safety of Patient 64 Pre-clinical Safety Assessment 64 Pre-Approval Safety Assessment in Humans 64 Safety Assessment during FDA Regulatory Review 65 Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Strategy – From Idea to IPO	Phase III	62
Pre-clinical Safety Assessment	Phase IV	62
Pre-Approval Safety Assessment in Humans 64 Safety Assessment during FDA Regulatory Review 65 Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy – From Idea to IPO 80 Equity capital 83	Regulation and Safety of Patient	64
Safety Assessment during FDA Regulatory Review Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Pre-clinical Safety Assessment	64
Post-Marketing Safety Supervision 65 Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 Sponsors 68 Sponsors 68 Totapter VI 70-77 Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 S) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Pre-Approval Safety Assessment in Humans	64
Placebo and other sides of a trial 66 Benefits and risks of participating in a clinical trial 67 What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Safety Assessment during FDA Regulatory Review	65
Benefits and risks of participating in a clinical trial What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI	Post-Marketing Safety Supervision	65
What are side effects and adverse reactions? 68 Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Placebo and other sides of a trial	66
Sponsors 68 7) Chapter VI 70-77 Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy – From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Benefits and risks of participating in a clinical trial	67
7) Chapter VI Business Plan and Business Planning Business Plan Business Plan Fixecutive Summary Mission statement Company description Technology Description Market Analysis Competitors and Competitiveness Strategy R&D People and Assumption Sum up 75 76 8) Chapter VII Financing: from Idea to IPO & Beyond Financing Strategy —From Idea to IPO Equity capital Angel Investments Yenture Investments Sas Venture Investments Bank Loans Bank Loans Bank Loans Bank Loans Bank Loans Bank Loans Executive Sumning 71 71 72 74 75 76 76 77 78 78 78 78 78 78 78	What are side effects and adverse reactions?	68
Business Plan and Business Planning	Sponsors	68
Business Plan and Business Planning 71 Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy — From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	7) Chapter VI	70-77
Business Plan 71 Executive Summary 71 Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy – From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85		71
Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85		71
Mission statement 72 Company description 72 Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Executive Summary	71
Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	· · · · · · · · · · · · · · · · · · ·	72
Technology Description 72 Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Company description	72
Market Analysis 73 Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	Technology Description	72
Competitors and Competitiveness 74 Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85		73
Strategy 74 R&D 75 People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	· · · · · · · · · · · · · · · · · · ·	74
People and Assumption 76 Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85		74
Sum up 77 8) Chapter VII 78-85 Financing: from Idea to IPO & Beyond 79 Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	R&D	75
8) Chapter VII Financing: from Idea to IPO & Beyond Financing Bioventure Financing Strategy –From Idea to IPO Equity capital Angel Investments Venture Investments Debt Capital Mezzanine Finance Bank Loans Convertible Loans 78-85 78-85 79 79 80 80 80 80 81 82 83 83 84 84 84 85 85	People and Assumption	76
Financing: from Idea to IPO & Beyond Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 85 Convertible Loans	Sum up	77
Financing: from Idea to IPO & Beyond Financing Bioventure 80 Financing Strategy –From Idea to IPO 80 Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 85 Convertible Loans	8) Chapter VII	78-85
Financing Bioventure Financing Strategy –From Idea to IPO Equity capital Angel Investments Venture Investments Debt Capital Mezzanine Finance Bank Loans Convertible Loans 80 80 81 82 83 84 84 84 85 86 87 88 88 88 88 88 88 88 88	_	
Financing Strategy –From Idea to IPO Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	·	80
Equity capital 83 Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	<u> </u>	
Angel Investments 83 Venture Investments 83 Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85	· · · · · · · · · · · · · · · · · · ·	
Venture Investments83Debt Capital84Mezzanine Finance84Bank Loans84Convertible Loans85	<u> </u>	
Debt Capital 84 Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85		
Mezzanine Finance 84 Bank Loans 84 Convertible Loans 85		
Bank Loans 84 Convertible Loans 85	<u> </u>	
Convertible Loans 85		
Corporate Bonds	Corporate Bonds	85

Government's role on a Bioventure development	85
9) Chapter VIII	86-91
Fund Raising for your Business	87
Investors	87
Executive Summery	88
VCs – an Introduction	88
Last Words	90
10) Chapter IX	92-98
Pitching the Bioventure Business	93
Strategic Plan for Media Relations	93
Less/Not so Expensive Media Exposure	94
Least Cost-effective Events for Bioventure	96
Expensive Media Exposure	96
Expected Expenditure	96
Communication Assets	97
What are the Communication Assets?	97
11) Chapter X	99-109
Role of Marketing Biotech Business	100
Crossing the Boundaries	101
Marketing begins in our life before we even know it	101
Basics of Marketing in Bioventure	102
Market Segments	102
Marketing, Niche Marketing & Scientists' Crossover	102
Niche Marketing Strategy	103
Platform Technologies	104
Services	104
Customized Reagent Supply	104
Generic Drug Manufacturing	104
Differential Strategy & Niche Marketing in Bio-business	104
Differential Model in Business	104
Fractional Differential Strategy	105
Earlier Differential Strategy	105
Differential Strategy & Time	106
Differential Strategy & Technology	107
Power of "DS"- From dust to Castle	107
Biopreneurs & "DS"	108
Biopreneurs and the Transaction Theory of Cost	108
Conclusion	108
12) Appendix I	110-120
Investment in the Biotech Industry	111
What are the views from the Investment community?	111
How do you view the Biotech investment market?	111
Where does the investment money tend to flow?	112
Key differences between biotech investment in USA and Japan	112
Which sector of the biotech offer short-term return and why?	113
Which sector of the biotech offers long-term return and why?	113
Should it be just about Financial Success?	114

Biotech business is more than just making money	115
How to evaluate biotech companies?	117
Key factors for evaluating a biotech company	118
Proprietary expertise	118
Robust pipeline and technology	118
Appropriate business model	118
Strong management	119
Financial resources	119
Market	119
13) Appendix II	121-131
Beginning of a Journey	122
Understanding Reality	124
Environment of Biotechnology in Japan (Outsiders Views)	126
Perspective of yesterdays	129
Analysis	130
Revenue Based business model bound to succeed	130
14) Appendix III	132-147
Biotechnology Industry Overview	133
The Major Segments in the Biotech Market	133
Europe	134
United Kingdom	134
Germany	134
Regulations in using Animals	135
Program Management from Contract Company	136
Full Program Management	136
Basic Program Management	136
Other Program Costs (Table)	137
What Japan Govt. could do to create a bioventure-based local economy?	137
Our Recommendation for stimulating the bio-economy in Japan	138
Investment in bioventures by VCs	140
Capital Market Financing for Biotechnology in Japan	142
The First Bioventure IPOs	142
Venture Capitalists (VCs) step in	143
Local Governments Entertain Vision of Breeding Bio-clusters	143
A Case Study for "DS" & Niche Marketing in Bio-business	144
Package of Studies to Assess Developability (Table)	145
List of Studies Needed for IND Registration (Table)	145
Optional Tests Depending on Phase I/IIa Strategy (Table)	146
Early Human Studies Aimed at Providing Clinical Proof of Concept (Table	
Investors Expectations of Share Price Growth (Chart)	147

Prelude

As we know that every business, whether it's related to inventive or innovative materials, has to face some ups and downs throughout its phases of development. Ultimately and quite fortunately a period appears that can offer some comfort and satisfaction to the followers of those businesses. But the true followers of any field urge neither satisfaction nor the comfort. It's the dedication, the zeal, the will-power to prove the prowess and not to forget the love for that subject that entices everyone to continue serving it. However, this is not the time to share words regarding any business material, as our prime concern in this book is Bioventure.

Bioventure represents a large world being concentrated in a small word. And as far as biopreneurs are concerned we have to delineate the scenario with a different temperature of light. It's really interesting and equally exciting a time for people intended to enjoy the world of bioventure. It's only because biotechnology, with emerging educational, governmental and industrial support, is gliding to its crest these days.

We may think of bioventure being an aerodynamic car based on three wheels – technology, management and capital. Each and every wheel is extremely sophisticated and must be taken care of in the most appropriate way to run the car to the best destination possible. After spending so many years in the learning and teaching process when I joined the practical field of concrete business I realized the need of proper understanding of characteristics of those three wheels. As people from the field of research work and management we may either know the better issues related to our own fields but to be a biopreneur we have to have a good hold to all the aspects of bio-business.

Again, when we look at the world of bioventure we find several people intended to invest but due to the lack of proper knowledge they feel better stay away. There are many institutions having the potential to expand their path by meeting only a few requirements such as patenting their ideas and technology. Sometimes, just having enough information and knowledge about selling their intellectual property or any research-based material to some pharmaceutical establishments may help the budding ventures to rise properly. But here also, it's the insufficiency of information that forces them to stay behind.

When these realizations struck my mind I felt the lack of only one very special item in our vicinity that can solve each of our problems. And that very special item is a good study material that may be of assistance to all the people included in the field of bioventure. What I mean is that it must contain material for all including upcoming entrepreneurs, people from the field of management and investors. And it is not only to serve the purpose of getting people from various fields under the same roof of bioventure but also to create the feelings of togetherness.

Working together has always been a fun to people like us. Now we are going to have the same fun multiplied many times by doing well to *hoi polloi* with our invented drugs and many other biotechnological products. At the same time there will an added satisfaction waiting for everyone concerned to the business in the form of capital. And to be very honest that'll be just the future that I dreamt of for bioventure. The best possible future of the bioventure relies upon the understanding among people associated in the business. And it'll

be possible only if we can assimilate the knowledge to run on other's fields. If we can understand the view that other people want to express and the vice versa then the treasure trove of bioventure is not far away.

Keeping all the aspects in mind I started writing this book and now that the book is ready to start its journey I hope it'll travel the longest way to bind the whole world together to cheer for a better future of bioventure. As we all know every business have its commercial aspect and it must be but at the same time we must keep our eyes open for the humanitarian views of the business concerned. I have tried to focus on that part of bioventure so that VCs and other investors along with biopreneurs can always remember their actual goal of helping needy people. Money will flow if consumers are there to buy product and exactly that'll happen if we don't forget them.

My book is targeted for everyone associated in the field of bioventure. Whether you are preparing to start a business, an intended investor, a person from the field of management or you are good at research, you all may and must read the book. Here I have tried a lot to say but possibly have missed some good words, which I'll definitely try to recap and put on papers in the next possible issue. All I need is a response from you so that I can comprehend that you also want to make it a continuous conversational process to exchange thoughts on bioventure. After all we together can build the future world of bioventure as by putting the fragments of our dreams together.





Writers' Opinion

Writing the book, "Biopreneurs: The Molecular Millionaires" we, Ryan Baidya and Miyuki Shiratani, have tried to cover the ordinary and extraordinary resources that readers can utilize to understand the biotech industry. While writing the book, we even have thought for those without biotech backgrounds. Thus, the book does not emphasize dry facts from the life science subject, or financial figures from the stock market. It is, rather, a lucid situational analysis of the biotech industry.

It offers a historical perspective of the biotech industry, advancement of biotech industry in relation to the recent growth and excitement of genomics and tissue regeneration sciences. "Biopreneurs: The Molecular Millionaires" has also covered the highlights for investing in specific areas of biotechnology, for instance, diabetes, cancer, strokes, age-related diseases, etc. It also strives to identify, analyze and educate prospective investors about how and why to invest in startup ventures, early-stage companies and mid-sized corporations. In addition, it will also provide tools, knowledge, and expertise to identify appropriate time to realize profits in a particular field, which will be done using a three-dimensional model for the biotech industry. In a nutshell, we have earnestly desired to incorporate as much information as possible to make the book a best friend, philosopher and guide for the people interested in biotechnology.

We are proud as Biopreneurs...we are again, proud serving you...